Syno One XL Large Joint Pain Management with Extended Coverage

Undertreated hip and shoulder pain drives significant disability and opioid escalation. Syno One XL's adequate joint coverage directly addresses the inadequate distribution problem that limits analgesic outcomes with standard-volume formulations in large joints.

Prospective data from hip OA cohorts shows mean VAS reduction of 42% at 12 weeks versus 24% with standard-volume HA, attributable to improved joint space coverage. Shoulder pain outcomes data demonstrate significant ASES and DASH score improvements at 12 and 26 weeks in patients with glenohumeral OA treated with Syno One XL. Opioid reduction of 35% at six months was documented in a real-world hip pain registry study of patients receiving repeat Syno One XL treatment cycles. Functional improvements in gait, range of motion, and daily activity scores correlate strongly with pain relief outcomes across all large joint indications studied.

Imaging-guided administration is mandatory for hip injections; combination with post-injection physiotherapy produces superior pain and function outcomes versus injection alone. Suitable for integration into interdisciplinary pain clinic programmes as a non-opioid, non-systemic large joint analgesic option with a favourable safety and tolerability profile. Pain diary and patient-reported outcome measure tracking recommended from injection date to quantify individual analgesic response and inform retreatment timing decisions. Well tolerated in elderly patients and those with significant comorbidities where systemic analgesic options are limited by tolerability or interaction risk.